Management of metabolic dysfunction–associated steatotic liver disease (MASLD)—An expert consensus statement from Indian diabetologists' perspective

Zargar, A H and Bhansali, A and Majumdar, A and Maheshwari, A and Bhattacharyya, A and Dasgupta, A and Saboo, B D and Sethi, B K and Sanyal, D and Seshadri, K G and Deshpande, N R and Kapoor, N and Lakhani, O J and Talwalkar, P G and Kalra, P and Mehrotra, R N and Sahay, R K and Shukla, R and Kant, S and Das, S and Agarwal, S C and Phatak, S R and G, Shanmugasundar and Joshi, S R and Shaikh, S S and Aravind, S R and Goswami, S and Ghosh, S and Panikar, V K and Mohan, V (2025) Management of metabolic dysfunction–associated steatotic liver disease (MASLD)—An expert consensus statement from Indian diabetologists' perspective. Diabetes, Obesity and Metabolism, 27 (S4). p. 3. ISSN 1462-8902

[img]
Preview
PDF
3271Kb

Abstract

In India, the increasing prevalence of diabetes and obesity poses a significant threat towards a surge in the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). Concomitant with the evolving guidelines, there is a need to direct and spread awareness among practicing diabetologists to identify and screen high-risk individuals for MASLD for timely management. Its asymptomatic nature and the evolving guidelines on diagnosis have hindered the precise estimates of MASLD in the high-risk group of individuals in a clinical setting. Therefore, an expert panel of diabetologists from India convened to review, discuss and document the approach towards screening, diagnosis and management of MASLD. Serum biomarkers, simple non-invasive tools and imaging techniques could direct the risk stratification of the patients. Early lifestyle interventions including weight loss and exercise are beneficial. The pharmacological landscape of drugs directed to insulin resistance, lipid metabolism, oxidative stress, inflammation, apoptosis and fibrogenesis pathways for the management of MASLD is expanding. In summary, the consensus statements are expected to serve as a useful guide in the screening and management of MASLD in the region and to direct a well-planned study design that could enhance the scientific value of these statements.

Item Type:Article
Official URL/DOI:http://dx.doi.org/10.1111/dom.16496
Uncontrolled Keywords: India; diabetologist; metabolic dysfunction‐associated steatotic liver disease; prognosis scoring; risk stratification; screening; serum biomarkers; transient elastography; type 2 diabetes mellitus
Subjects:Diabetes Epidemiology
Diabetes
Divisions:Department of Epidemiology
Department of Diabetology
ID Code:1501
Deposited By:surendar radha
Deposited On:25 Jun 2025 10:27
Last Modified:25 Jun 2025 10:27

Repository Staff Only: item control page